相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。HER2 in metastatic colorectal cancer: a new to target to remember
Lynn Bitar et al.
BIOMARKERS IN MEDICINE (2021)
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colrectal cancer: the phase II HERACLES-B trial
Andrea Sartore-Bianchi et al.
ESMO OPEN (2020)
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
Funda Meric-Bemstam et al.
LANCET ONCOLOGY (2019)
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer
Andrea Sartore-Bianchi et al.
ONCOLOGIST (2019)
Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas
Xin-Yu Wang et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2019)
Targeting HER2 in Colorectal Cancer: The Landscape of Amplification and Short Variant Mutations in ERBB2 and ERBB3
Jeffrey S. Ross et al.
CANCER (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Colorectal Cancer Initial Diagnosis: Screening Colonoscopy, Diagnostic Colonoscopy, or Emergent Surgery, and Tumor Stage and Size at Initial Presentation
Courtney C. Moreno et al.
CLINICAL COLORECTAL CANCER (2016)
HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials
Susan D. Richman et al.
JOURNAL OF PATHOLOGY (2016)
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore-Bianchi et al.
LANCET ONCOLOGY (2016)
The genomic landscape of response to EGFR blockade in colorectal cancer
Andrea Bertotti et al.
NATURE (2015)
HER2/neu testing in primary colorectal carcinoma
B. Ingold Heppner et al.
BRITISH JOURNAL OF CANCER (2014)
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
Kimio Yonesaka et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
A Molecularly Annotated Platform of Patient-Derived Xenografts (Xenopatients) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
Andrea Bertotti et al.
CANCER DISCOVERY (2011)
Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?
Dara O. Kavanagh et al.
BMC CANCER (2009)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
分享论文
